Research Article Volume 14 Issue 11 - 2025

Synthetic vs Biologic Graft Sacrocolpopexy for Pelvic Organ Prolapse

Jessica Vo1,2*, Ryan Ting2, Sireen Jaber1,3, Stewart McNamara1,2, Amani Harris1,3, Andrew Zuschmann1,3, Danendran Krishnan1,3, Nancy Peters1,3 and Dean Conrad1,3

1Department of Gynaecology, The Sutherland Hospital, Kareena Rd Caringbah, NSW, Australia

2University of New South Wales, Australia

3Sydney Minimally Invasive Gynaecology, Australia

*Corresponding Author: Jessica Vo, Department of Gynaecology, The Sutherland Hospital, Kareena Rd Caringbah, NSW and University of New South Wales, Australia.
Received: October 16, 2025; Published: November 07, 2025



Background: Pelvic organ prolapse is a prevalent condition affecting up to 40% of women globally. Sacrocolpopexy remains the gold-standard surgical treatment, traditionally utilising synthetic materials such as polypropylene, however growing interests in biologic grafts have raised questions about their relative performance. This systematic review and meta-analysis compares objective (POP-Q stage 0) and clinical (POP-Q stage 1) cure rates between synthetic and biologic grafts 12 months post sacrocolpopexy.

Methods: A systematic search of PubMed and Scopus was conducted in line with PRISMA guidelines. Studies comparing POP-Q outcomes at 12 months post sacrocolpopexy were included. Data extraction was performed, and a meta-analysis was conducting using a DerSimonian and Laird random-effects model, reporting outcomes as odds ratios (OR) and 95% confidence intervals (CI).

Results: Five studies comprising 600 participants (304 synthetic, 296 biologic) met the inclusion criteria. Among three studies reporting objective cure, 81% of biologic and 77.4% of synthetic graft recipients demonstrated successful outcomes, with no significant difference (OR 0.563; 95% CI 0.121-2.617). Four studies reported clinical cure, with success rates of 66.7% and 68.5%, respectively (OR 0.695; 95% CI 0.263-1.840). Sensitivity analysis demonstrated significantly higher clinical cure rates in the synthetic cohort (OR 0.465; 95% CI 0.254-0.854).

Conclusion: While synthetic and biologic grafts yielded comparable objective cure rates, sensitivity analysis suggested superior clinical outcomes with synthetic materials. The heterogeneity of biologic grafts complicates direct comparisons, highlighting the need for standardized outcome reporting and further research to guide graft selection in sacrocolpopexy.

 Keywords: Prolapse; Sacrocolpopexy; Mesh; Biologics; Graft; Urogynaecology

  1. Barker TH., et al. “The revised JBI critical appraisal tool for the assessment of risk of bias for randomized controlled trials”. JBI Evidence Synthesis 3 (2023): 494-506.
  2. Bock Megan E., et al. “Robotic sacral colpopexy using autologous fascia lata compared with mesh”. Journal of Endourology6 (2021): 801-807.
  3. Culligan Patrick J., et al. “A randomized controlled trial comparing fascia lata and synthetic mesh for sacral colpopexy”. Obstetrics and Gynecology1 (2005): 29-37.
  4. Culligan Patrick J., et al. “Long-term success of abdominal sacral colpopexy using synthetic mesh”. American Journal of Obstetrics and Gynecology6 (2002): 1473-1480; discussion 1481-1482.
  5. Culligan Patrick J., et al. “Porcine dermis compared with polypropylene mesh for laparoscopic sacrocolpopexy: a randomized controlled trial”. Obstetrics and Gynecology1 (2013): 143-151.
  6. Deprest Jan., et al. “Medium term outcome of laparoscopic sacrocolpopexy with xenografts compared to synthetic grafts”. The Journal of Urology5 (2009): 2362-2368.
  7. Gregory W Thomas., et al. “Surgical outcome of abdominal sacrocolpopexy with synthetic mesh versus abdominal sacrocolpopexy with cadaveric fascia lata”. International Urogynecology Journal and Pelvic Floor Dysfunction 5 (2005): 369-374.
  8. Maher Christopher., et al. “Surgical management of pelvic organ prolapse in women”. The Cochrane Database of Systematic Reviews 4 (2013): CD004014.
  9. Page Matthew J., et al. “The PRISMA 2020 Statement: An updated guideline for reporting systematic reviews”. British Medical Journal 372 (2021): n71.
  10. Quiroz Lieschen H., et al. “Abdominal sacrocolpopexy: anatomic outcomes and complications with pelvicol, autologous and synthetic graft materials”. American Journal of Obstetrics and Gynecology 5 (2008): 557.e1-557.e5.
  11. Schulten Sascha FM., et al. “Risk factors for primary pelvic organ prolapse and prolapse recurrence: an updated systematic review and meta-analysis”. American Journal of Obstetrics and Gynecology 2 (2022): 192-208.
  12. Tate Susan B., et al. “Randomized trial of fascia lata and polypropylene mesh for abdominal sacrocolpopexy: 5-year follow-up”. International Urogynecology Journal 2 (2011): 137-143.
  13. Wang Bo., et al. “Global burden and trends of pelvic organ prolapse associated with aging women: an observational trend study from 1990 to 2019”. Frontiers in Public Health 10 (2022): 975829.
  14. Wang Rui., et al. “Sacrocolpopexy using autologous rectus fascia: cohort study of long-term outcomes and complications”. BJOG: An International Journal of Obstetrics and Gynaecology9 (2022): 1600-1606.

Jessica Vo., et al. “Synthetic vs Biologic Graft Sacrocolpopexy for Pelvic Organ Prolapse”. EC Gynaecology  14.11 (2025): 01-09.